首页 > 最新文献

Current drug discovery technologies最新文献

英文 中文
Novel Approaches for the Enhancement of Bioavailability of Drugs: An Updated Review. 提高药物生物利用度的新方法:最新综述。
Pub Date : 2024-08-09 DOI: 10.2174/0115701638311058240806100555
Jyoshna Rani Dash, Gurudutta Pattnaik, Himansu Bhusan Samal, Gangadhar Pradhan, Choudhury Pratyush Kumar Baral, Biswajit Behera, Biswakanth Kar

In medicine, bioavailability is the percentage of a drug that enters the bloodstream and can be used to treat a patient. It has proven challenging throughout time to develop techniques that allow oral administration of most drugs, regardless of their properties, to achieve therapeutic systemic availability. This will be an impressive feat, considering that over 90% of pharmaceuticals are known to have limitations on their oral bioavailability. Improving bioavailability is crucial for optimizing the efficacy and safety of drugs. This review covers a wide range of techniques, including physical, chemical, and formulation approaches, highlighting their mechanisms, advantages, and limitations. Inhibitions of efflux pumps, inhibition of presystemic metabolism, and innovative drug delivery systems that capitalize on the gastrointestinal regionality of medicines are some of the new techniques that have drawn increased interest. Nanotechnology in pharmaceuticals is also being used in this field. We have collected the literature data from 2009 to 2024 using Science Direct, PubMed/Medline, Scopus, and Google Scholar.

在医学中,生物利用度是指进入血液并可用于治疗病人的药物比例。事实证明,无论药物的特性如何,要想开发出让大多数药物的口服给药达到治疗性全身可用性的技术,始终是一项挑战。考虑到已知 90% 以上的药物在口服生物利用度方面存在限制,这将是一项了不起的成就。提高生物利用度对于优化药物的疗效和安全性至关重要。本综述涵盖各种技术,包括物理、化学和制剂方法,重点介绍其机制、优势和局限性。抑制外排泵、抑制系统前代谢以及利用药物的胃肠道区域性的创新给药系统等新技术引起了越来越多的关注。纳米制药技术也被应用于这一领域。我们利用 Science Direct、PubMed/Medline、Scopus 和 Google Scholar 收集了 2009 年至 2024 年的文献数据。
{"title":"Novel Approaches for the Enhancement of Bioavailability of Drugs: An Updated Review.","authors":"Jyoshna Rani Dash, Gurudutta Pattnaik, Himansu Bhusan Samal, Gangadhar Pradhan, Choudhury Pratyush Kumar Baral, Biswajit Behera, Biswakanth Kar","doi":"10.2174/0115701638311058240806100555","DOIUrl":"https://doi.org/10.2174/0115701638311058240806100555","url":null,"abstract":"<p><p>In medicine, bioavailability is the percentage of a drug that enters the bloodstream and can be used to treat a patient. It has proven challenging throughout time to develop techniques that allow oral administration of most drugs, regardless of their properties, to achieve therapeutic systemic availability. This will be an impressive feat, considering that over 90% of pharmaceuticals are known to have limitations on their oral bioavailability. Improving bioavailability is crucial for optimizing the efficacy and safety of drugs. This review covers a wide range of techniques, including physical, chemical, and formulation approaches, highlighting their mechanisms, advantages, and limitations. Inhibitions of efflux pumps, inhibition of presystemic metabolism, and innovative drug delivery systems that capitalize on the gastrointestinal regionality of medicines are some of the new techniques that have drawn increased interest. Nanotechnology in pharmaceuticals is also being used in this field. We have collected the literature data from 2009 to 2024 using Science Direct, PubMed/Medline, Scopus, and Google Scholar.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141918387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Genus Paeonia: A Review of the Targeted Signaling Pathways and Underlying Mechanisms of Pharmacological and Clinical Properties. 芍药属:芍药属植物:药理和临床特性的靶向信号通路及基本机制综述》。
Pub Date : 2024-07-10 DOI: 10.2174/0115701638318395240703115522
Atefeh Jalali, Fereshteh Jafari, Shima Behnamrad, Mohammad M Zarshenas, Xiuxin Zhang, Ali Kashkooe

Introduction: The Paeoniaceae family contains only the Paeonia genus and is considered the major group of flowering plants. Several traditional and pharmacological applications of Paeoniaceae herbs have been described. The current paper aimed to determine the pharmacological activities of the most prevalent herbs from the genus Paeonia by focusing on the underlying mechanism of action and signaling pathways to provide insight for further in-depth research on the medicinal resources of Paeonia.

Method: The "Paeoniaceae" keyword was searched from 1st January 1995 to 15th May 2024 through the PubMed and Scopus databases. Only papers related to pharmacology, pharmaceutics, and toxicology were extracted. The possible pharmacological activity of the Paeonia plants underlying their mechanism of action and signaling pathways was subsequently discussed.

Results: Following our venture, only 15 Paeonia herbs were adequately evaluated for their pharmacological applications. Paeonia lactiflora Pall., Paeonia suffruticosa Andrews, and Paeonia emodi Royle are among the most prevalent Paeonia plants that have attracted increased amounts of attention in modern pharmacological studies. Paeonia herbs possess various pharmacological applications, such as anti-inflammatory, anti-allergic, anticancer, antimicrobial, cardiovascular protective, cosmetic and skincare, radical scavenging, hepatoprotective and anti-ulcerative, anti-diabetic, musculoskeletal, and neuroprotective effects, and can be used as alternative therapies under critical medical conditions.

Conclusion: Among the applications of Paeonia herbs, anti-inflammatory and antioxidant activities are critical, as most of the other pharmacological effects are attributed to them. In other words, nuclear factor (NF)-κB and nuclear factor erythroid 2-related factor 2 (Nrf2) can be considered the most important signaling pathways involved in the pharmacological activity of Paeonia herbs.

简介芍药科只有芍药属,被认为是开花植物的主要类群。芍药科草本植物的一些传统和药理应用已被描述。本文旨在确定芍药属最常用草药的药理活性,重点研究其潜在的作用机制和信号传导途径,为进一步深入研究芍药的药用资源提供见解:方法:通过 PubMed 和 Scopus 数据库对 1995 年 1 月 1 日至 2024 年 5 月 15 日期间的 "芍药属 "关键词进行检索。只提取了与药理学、药剂学和毒理学相关的论文。随后讨论了芍药可能具有的药理活性及其作用机制和信号传导途径:根据我们的研究,只有 15 种芍药的药理应用得到了充分评估。Paeonia lactiflora Pall.、Paeonia suffruticosa Andrews 和 Paeonia emodi Royle 是最常见的芍药植物,它们在现代药理学研究中引起了越来越多的关注。芍药具有多种药理作用,如消炎、抗过敏、抗癌、抗菌、保护心血管、美容护肤、清除自由基、保肝和抗溃疡、抗糖尿病、肌肉骨骼和神经保护作用,可作为危重病人的替代疗法:在芍药的应用中,抗炎和抗氧化活性至关重要,因为其他大多数药理作用都归功于它们。换言之,核因子(NF)-κB 和核因子红细胞 2 相关因子 2(Nrf2)可被视为参与芍药药理活性的最重要信号通路。
{"title":"The Genus Paeonia: A Review of the Targeted Signaling Pathways and Underlying Mechanisms of Pharmacological and Clinical Properties.","authors":"Atefeh Jalali, Fereshteh Jafari, Shima Behnamrad, Mohammad M Zarshenas, Xiuxin Zhang, Ali Kashkooe","doi":"10.2174/0115701638318395240703115522","DOIUrl":"https://doi.org/10.2174/0115701638318395240703115522","url":null,"abstract":"<p><strong>Introduction: </strong>The Paeoniaceae family contains only the Paeonia genus and is considered the major group of flowering plants. Several traditional and pharmacological applications of Paeoniaceae herbs have been described. The current paper aimed to determine the pharmacological activities of the most prevalent herbs from the genus Paeonia by focusing on the underlying mechanism of action and signaling pathways to provide insight for further in-depth research on the medicinal resources of Paeonia.</p><p><strong>Method: </strong>The \"Paeoniaceae\" keyword was searched from 1st January 1995 to 15th May 2024 through the PubMed and Scopus databases. Only papers related to pharmacology, pharmaceutics, and toxicology were extracted. The possible pharmacological activity of the Paeonia plants underlying their mechanism of action and signaling pathways was subsequently discussed.</p><p><strong>Results: </strong>Following our venture, only 15 Paeonia herbs were adequately evaluated for their pharmacological applications. Paeonia lactiflora Pall., Paeonia suffruticosa Andrews, and Paeonia emodi Royle are among the most prevalent Paeonia plants that have attracted increased amounts of attention in modern pharmacological studies. Paeonia herbs possess various pharmacological applications, such as anti-inflammatory, anti-allergic, anticancer, antimicrobial, cardiovascular protective, cosmetic and skincare, radical scavenging, hepatoprotective and anti-ulcerative, anti-diabetic, musculoskeletal, and neuroprotective effects, and can be used as alternative therapies under critical medical conditions.</p><p><strong>Conclusion: </strong>Among the applications of Paeonia herbs, anti-inflammatory and antioxidant activities are critical, as most of the other pharmacological effects are attributed to them. In other words, nuclear factor (NF)-κB and nuclear factor erythroid 2-related factor 2 (Nrf2) can be considered the most important signaling pathways involved in the pharmacological activity of Paeonia herbs.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatoprotective Potential of Murraya koenigii (Curry Leaves) against Xenobiotics, Heavy Metals, and Hepatotoxic Agents: A Comprehensive Review. Murraya koenigii(咖喱叶)对异种生物、重金属和肝毒性物质的肝脏保护潜力:全面综述。
Pub Date : 2024-07-08 DOI: 10.2174/0115701638310869240628060001
Rohit Gangawat, Ronit Parashar, Ritu Kamal Yadav

Liver disease, responsible for two million annual deaths, causes Chronic Liver Disease (CLD) and cirrhosis, causing roughly a million deaths yearly. Treatment options for liver injury induced by hepatotoxicity vary, including medication (N-acetylcysteine, corticosteroids, and ursodeoxycholic acid), lifestyle changes, and sometimes liver transplant. However, effectiveness varies, and some treatments carry risks and side effects, highlighting the need for improved therapeutic approaches. Murraya koenigii (MK) is known for its hepatoprotective, antioxidant, anti-inflammatory, anti-microbial, nephroprotective, hepatoprotective, gastroprotective, cardioprotective, neuroprotective, wound-healing, anti-cancerous and immunomodulatory effects, etc. This review highlights the effectiveness of MK against liver damage induced by heavy metals, drug abuse, xenobiotics, etc. A comprehensive search across multiple databases like PubMed, Google Scholar, and others for articles on various hepatotoxicants and hepatoprotective activity of MK was conducted. The researchers applied specific search terms and limits, resulting in 149 eligible articles for final analysis, meeting predetermined inclusion criteria and excluding irrelevant studies. According to the available literature, the phytochemical components of MK, such as flavonoids, tannins, and alkaloids present in various extracts, play a crucial role in reversing the hepatotoxic effects by modifying oxidative and ER stresses, re-establishing the hepatic biochemical markers and enzymes involved in metabolism denoting ameliorative activity, and controlling the expression of pro-inflammatory cytokines. To conclude, this review highlights that MK has great potential as a natural hepatoprotective agent, providing a versatile defense against a range of injuries caused by heavy metals, xenobiotics, and common hepatotoxic agents.

肝病每年造成 200 万人死亡,其中慢性肝病(CLD)和肝硬化每年造成约 100 万人死亡。治疗肝毒性引起的肝损伤的方法多种多样,包括药物治疗(N-乙酰半胱氨酸、皮质类固醇和熊去氧胆酸)、改变生活方式,有时还包括肝移植。然而,治疗效果各不相同,有些治疗方法还存在风险和副作用,因此需要改进治疗方法。Murraya koenigii(MK)具有保肝、抗氧化、抗炎、抗微生物、肾保护、肝保护、胃保护、心脏保护、神经保护、伤口愈合、抗癌和免疫调节等功效。本综述强调了 MK 对重金属、药物滥用、异种生物等引起的肝损伤的有效性。研究人员在 PubMed、Google Scholar 等多个数据库中对有关 MK 的各种肝毒性和肝保护活性的文章进行了全面搜索。研究人员使用了特定的搜索条件和限制,最终分析了 149 篇符合预定纳入标准的文章,并排除了不相关的研究。根据现有文献,MK 的植物化学成分,如各种提取物中的黄酮类、单宁酸和生物碱,通过改变氧化和 ER 压力、重建肝脏生化标志物和参与新陈代谢的酶表示改善活性,以及控制促炎细胞因子的表达,在逆转肝毒性效应方面发挥了重要作用。总之,这篇综述强调了 MK 作为一种天然肝脏保护剂的巨大潜力,它能提供多种防御手段,抵御重金属、异种生物毒素和常见肝毒性物质造成的一系列损伤。
{"title":"Hepatoprotective Potential of Murraya koenigii (Curry Leaves) against Xenobiotics, Heavy Metals, and Hepatotoxic Agents: A Comprehensive Review.","authors":"Rohit Gangawat, Ronit Parashar, Ritu Kamal Yadav","doi":"10.2174/0115701638310869240628060001","DOIUrl":"https://doi.org/10.2174/0115701638310869240628060001","url":null,"abstract":"<p><p>Liver disease, responsible for two million annual deaths, causes Chronic Liver Disease (CLD) and cirrhosis, causing roughly a million deaths yearly. Treatment options for liver injury induced by hepatotoxicity vary, including medication (N-acetylcysteine, corticosteroids, and ursodeoxycholic acid), lifestyle changes, and sometimes liver transplant. However, effectiveness varies, and some treatments carry risks and side effects, highlighting the need for improved therapeutic approaches. Murraya koenigii (MK) is known for its hepatoprotective, antioxidant, anti-inflammatory, anti-microbial, nephroprotective, hepatoprotective, gastroprotective, cardioprotective, neuroprotective, wound-healing, anti-cancerous and immunomodulatory effects, etc. This review highlights the effectiveness of MK against liver damage induced by heavy metals, drug abuse, xenobiotics, etc. A comprehensive search across multiple databases like PubMed, Google Scholar, and others for articles on various hepatotoxicants and hepatoprotective activity of MK was conducted. The researchers applied specific search terms and limits, resulting in 149 eligible articles for final analysis, meeting predetermined inclusion criteria and excluding irrelevant studies. According to the available literature, the phytochemical components of MK, such as flavonoids, tannins, and alkaloids present in various extracts, play a crucial role in reversing the hepatotoxic effects by modifying oxidative and ER stresses, re-establishing the hepatic biochemical markers and enzymes involved in metabolism denoting ameliorative activity, and controlling the expression of pro-inflammatory cytokines. To conclude, this review highlights that MK has great potential as a natural hepatoprotective agent, providing a versatile defense against a range of injuries caused by heavy metals, xenobiotics, and common hepatotoxic agents.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141565381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthesis, Molecular Docking, and Antimicrobial Evaluation of 2-(Substituted Amino)-N-(6-Substituted-1,3-Benzothiazol-2yl) Acetamide. 2-(取代氨基)-N-(6-取代-1,3-苯并噻唑-2-基)乙酰胺的合成、分子对接和抗菌评价。
Pub Date : 2024-06-20 DOI: 10.2174/0115701638299377240604112400
Smita Pawar, Amol Kale, Priya Zori, Dhanashri Zope

Background: The development of antimicrobial agents is crucial for several reasons, primarily to combat infectious diseases and to address the growing threat of antimicrobial resistance. The need for the contin-ued development of antimicrobial drugs persists despite the presence of many existing drugs for several reasons viz; emerging new pathogens and diseases, reistance to existing drug and propogation of multi-drug resistance to existing drugs.

Objective: The objective of the study was to synthesize and evaluate the antimicrobial potential of newly synthesized benzothiazole derivatives.

Methods: A new series of 2-(substituted amino)-N-(6-substituted-1,3-benzothiazol-2yl)acetamide BTC(a-t) has been synthesized by reacting it with chloracetyl chloride with substituted 2-amino benzothiazole and further refluxed with various substituted amines to obtain target compounds. The synthesized compounds were screened experimentally for their antimicrobial property against gram-positive and gram-negative bacteria and fungi. The zone of inhibition and minimum inhibitory concentration of compounds were determined against selected bacterial and fungal strains. Further docking study was carried out to check the probable interactions with the selected protein using V-life MDS 3.5 software (DNA gyrase, PDB: 3G75).

Result: Compounds BTC-j N-(6-methoxy-1,3-benzothiazol-2-yl)-2-(pyridine-3-ylamino)acetamide and BTC-r N-(6-nitro-1,3-benzothiazol-2-yl)-2-(pyridine-3-ylamino)acetamide were found to have good antimicrobial potential. The compound BTC-j showed good antibacterial activity against S. aureus at an MIC value of 12.5 μg/mL, B. subtilis at MIC of 6.25μg/mL, E. coli at MIC of 3.125μg/mL, and P. aeruginosa at MIC of 6.25μg/mL. Thus, from the result, it was observed that compounds BTC-j, BTC-f, BTC-n, and BTC-r exhibited significant antibacterial and antifungal potential at different concentrations.

Conclusion: The present study resulted in the successful synthesis of 2-acetamido substituted benzothiazole derivatives BTC(a-t) with good yields. The dock score of the compounds and the antimicrobial activity were found to be consistent. No statistical difference in the antimicrobial activity of the standard and test compounds was found, indicating that the test compounds have comparable activity. Therefore, benzothiazole linked to heterocyclic rings with an acetamide linkage may serve as promising lead molecules for further optimization in the journey to discover potent antibacterial agents. Thus, we conclude that the synthesized compounds have the potential for further development as novel antimicrobial agents.

背景:出于多种原因,开发抗菌剂至关重要,主要是为了防治传染病和应对日益严重的抗菌剂耐药性威胁。尽管存在许多现有药物,但由于新病原体和疾病的出现、对现有药物的抗药性以及对现有药物的多重抗药性的传播等原因,抗菌药物的持续开发仍有必要:本研究旨在合成和评估新合成的苯并噻唑衍生物的抗菌潜力:方法:通过氯乙酰氯与取代的 2-氨基苯并噻唑反应,合成了一系列新的 2-(取代氨基)-N-(6-取代-1,3-苯并噻唑-2 基)乙酰胺 BTC(a-t),并与各种取代胺进一步回流得到目标化合物。实验筛选了合成化合物对革兰氏阳性和阴性细菌及真菌的抗菌特性。对选定的细菌和真菌菌株测定了化合物的抑菌区和最低抑菌浓度。使用 V-life MDS 3.5 软件(DNA gyrase,PDB:3G75)进行了进一步的对接研究,以检查与所选蛋白质的可能相互作用:发现化合物 BTC-j N-(6-甲氧基-1,3-苯并噻唑-2-基)-2-(吡啶-3-基氨基)乙酰胺和 BTC-r N-(6-硝基-1,3-苯并噻唑-2-基)-2-(吡啶-3-基氨基)乙酰胺具有良好的抗菌潜力。化合物 BTC-j 对金黄色葡萄球菌(MIC 值为 12.5 μg/mL)、枯草杆菌(MIC 值为 6.25 μg/mL)、大肠杆菌(MIC 值为 3.125 μg/mL)和绿脓杆菌(MIC 值为 6.25 μg/mL)具有良好的抗菌活性。因此,从结果中可以看出,化合物 BTC-j、BTC-f、BTC-n 和 BTC-r 在不同浓度下具有显著的抗菌和抗真菌潜力:本研究成功合成了 2-乙酰氨基取代的苯并噻唑衍生物 BTC(a-t),产率良好。化合物的 dock 评分和抗菌活性一致。标准化合物和受试化合物的抗菌活性没有统计学差异,表明受试化合物具有相当的活性。因此,苯并噻唑与具有乙酰胺连接的杂环连接,可作为有希望的先导分子,在发现强效抗菌剂的过程中进一步优化。因此,我们得出结论:合成的化合物具有作为新型抗菌剂进一步开发的潜力。
{"title":"Synthesis, Molecular Docking, and Antimicrobial Evaluation of 2-(Substituted Amino)-N-(6-Substituted-1,3-Benzothiazol-2yl) Acetamide.","authors":"Smita Pawar, Amol Kale, Priya Zori, Dhanashri Zope","doi":"10.2174/0115701638299377240604112400","DOIUrl":"https://doi.org/10.2174/0115701638299377240604112400","url":null,"abstract":"<p><strong>Background: </strong>The development of antimicrobial agents is crucial for several reasons, primarily to combat infectious diseases and to address the growing threat of antimicrobial resistance. The need for the contin-ued development of antimicrobial drugs persists despite the presence of many existing drugs for several reasons viz; emerging new pathogens and diseases, reistance to existing drug and propogation of multi-drug resistance to existing drugs.</p><p><strong>Objective: </strong>The objective of the study was to synthesize and evaluate the antimicrobial potential of newly synthesized benzothiazole derivatives.</p><p><strong>Methods: </strong>A new series of 2-(substituted amino)-N-(6-substituted-1,3-benzothiazol-2yl)acetamide BTC(a-t) has been synthesized by reacting it with chloracetyl chloride with substituted 2-amino benzothiazole and further refluxed with various substituted amines to obtain target compounds. The synthesized compounds were screened experimentally for their antimicrobial property against gram-positive and gram-negative bacteria and fungi. The zone of inhibition and minimum inhibitory concentration of compounds were determined against selected bacterial and fungal strains. Further docking study was carried out to check the probable interactions with the selected protein using V-life MDS 3.5 software (DNA gyrase, PDB: 3G75).</p><p><strong>Result: </strong>Compounds BTC-j N-(6-methoxy-1,3-benzothiazol-2-yl)-2-(pyridine-3-ylamino)acetamide and BTC-r N-(6-nitro-1,3-benzothiazol-2-yl)-2-(pyridine-3-ylamino)acetamide were found to have good antimicrobial potential. The compound BTC-j showed good antibacterial activity against S. aureus at an MIC value of 12.5 μg/mL, B. subtilis at MIC of 6.25μg/mL, E. coli at MIC of 3.125μg/mL, and P. aeruginosa at MIC of 6.25μg/mL. Thus, from the result, it was observed that compounds BTC-j, BTC-f, BTC-n, and BTC-r exhibited significant antibacterial and antifungal potential at different concentrations.</p><p><strong>Conclusion: </strong>The present study resulted in the successful synthesis of 2-acetamido substituted benzothiazole derivatives BTC(a-t) with good yields. The dock score of the compounds and the antimicrobial activity were found to be consistent. No statistical difference in the antimicrobial activity of the standard and test compounds was found, indicating that the test compounds have comparable activity. Therefore, benzothiazole linked to heterocyclic rings with an acetamide linkage may serve as promising lead molecules for further optimization in the journey to discover potent antibacterial agents. Thus, we conclude that the synthesized compounds have the potential for further development as novel antimicrobial agents.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141443965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel Targets for the Development of Tuberculosis Vaccine. 开发结核病疫苗的新目标。
Pub Date : 2024-06-07 DOI: 10.2174/0115701638285518240601075811
Rushika Joshi, Devang Sheth, Jayesh Beladiya, Chirag Patel, Nilay Solanki, Mittal Dalal, Ashish Kyada, Sandip B Patel

In underdeveloped nations, tuberculosis (TB) continues to be a major source of morbidity and mortality. The currently available vaccine against tuberculosis in endemic areas is mainly ineffective, which triggers the need for a clinically effective vaccine against tuberculosis. In the present review, we emphasized the impact of genetic variations in the BCG strains, which influence the efficacy of BCG vaccines. We also discussed the current status of BCG vaccines and their potential mechanisms on the modulation of B cells and, thereby, humoral immunity, which trigger immune responses against various intracellular pathogens. Further, we also elaborated upon the pre-clinical and clinical studies demonstrating the efficacy and safety of the vaccines. Moreover, we also presented the putative novel targets such as polysaccharide-induced antibodies for the protection against Mtb, PGRS domain as an important target for Humoral immunity, HLA-E pathway-Target strategy for new TB vaccine, Coronin-1a - Novel player for Mycobacterial survival, IRGM, IFN-I3, an autophagy inducer with Irgm1 serving as a core part in the Tuberculosis vaccine development.

在欠发达国家,结核病(TB)仍然是发病和死亡的主要原因。在结核病流行地区,目前可用的结核病疫苗主要是无效的,因此需要一种临床有效的结核病疫苗。在本综述中,我们强调了卡介苗菌株基因变异的影响,这种变异会影响卡介苗的效力。我们还讨论了卡介苗的现状及其对 B 细胞的潜在调节机制,以及由此产生的体液免疫,从而引发针对各种细胞内病原体的免疫反应。此外,我们还阐述了证明疫苗有效性和安全性的临床前和临床研究。此外,我们还介绍了一些推测的新靶点,如多糖诱导的抗体对 Mtb 的保护作用、PGRS 结构域作为体液免疫的重要靶点、HLA-E 通路--新型结核病疫苗的靶点策略、Coronin-1a--分枝杆菌生存的新角色、IRGM、IFN-I3--自噬诱导剂,以及作为结核病疫苗开发核心部分的 Irgm1。
{"title":"Novel Targets for the Development of Tuberculosis Vaccine.","authors":"Rushika Joshi, Devang Sheth, Jayesh Beladiya, Chirag Patel, Nilay Solanki, Mittal Dalal, Ashish Kyada, Sandip B Patel","doi":"10.2174/0115701638285518240601075811","DOIUrl":"https://doi.org/10.2174/0115701638285518240601075811","url":null,"abstract":"<p><p>In underdeveloped nations, tuberculosis (TB) continues to be a major source of morbidity and mortality. The currently available vaccine against tuberculosis in endemic areas is mainly ineffective, which triggers the need for a clinically effective vaccine against tuberculosis. In the present review, we emphasized the impact of genetic variations in the BCG strains, which influence the efficacy of BCG vaccines. We also discussed the current status of BCG vaccines and their potential mechanisms on the modulation of B cells and, thereby, humoral immunity, which trigger immune responses against various intracellular pathogens. Further, we also elaborated upon the pre-clinical and clinical studies demonstrating the efficacy and safety of the vaccines. Moreover, we also presented the putative novel targets such as polysaccharide-induced antibodies for the protection against Mtb, PGRS domain as an important target for Humoral immunity, HLA-E pathway-Target strategy for new TB vaccine, Coronin-1a - Novel player for Mycobacterial survival, IRGM, IFN-I3, an autophagy inducer with Irgm1 serving as a core part in the Tuberculosis vaccine development.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141302286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding the Potential of CBD for Health Benefits: an Overview. 了解 CBD 为健康带来益处的潜力:概述。
Pub Date : 2024-06-06 DOI: 10.2174/0115701638305553240529103622
Ivan Santos, M Beatriz P P Oliveira, Ana Casas, Javier Fidalgo, Hugo Almeida

Cannabinoids are compounds with increasing scientific interest, particularly due to their interaction with the endocannabinoid system via CBR1 and CBR2 receptors. They can interfere with appetite, pain, and sleep or develop mood changes of the individual. Cannabidiol (CBD) is a well-known cannabinoid with potential benefits, including reducing epilepsy seizures, alleviating anxiety, and obsessive-compulsive disorder (OCD) symptoms, aiding in Tourette Syndrome (a neurodevelopmental disorder), depression, sleep disorders, and promising in the treatment of cancer, pain relief, and heart health. Although generally safe, CBD can have side effects, including drug metabolism interference, fertility, and liver function. In addition, it can be administered by oral, sublingual, transdermal or inhalation via, each one with different bioavailability. The application of nanotechnology, specifically through colloidal carrier systems, holds promising potential for maximizing CBD's efficacy and pharmacological profile. There are reported CBD extraction methods using ethanol, carbon dioxide, deionised water, and non-polar oils like olive or coconut oil. The green extraction methods have gained popularity for their higher yields, shorter extraction time, and reduced costs. A specific dose with the desired effects is challenging due to individual factors, with most studies suggesting a range between less than 1 and 50 mg/kg/d. This review aims to explore the principles of CBD-based products development, focusing on extraction methods and purification processes of this cannabinoid for tinctures, topicals, and other pharmaceutical forms, as well as further research to attain the objectives.

科学界对大麻素这种化合物的兴趣与日俱增,特别是因为大麻素通过 CBR1 和 CBR2 受体与内源性大麻素系统相互作用。它们会影响食欲、疼痛和睡眠,或导致个人情绪变化。大麻二酚(CBD)是一种众所周知的大麻素,具有潜在的益处,包括减少癫痫发作、缓解焦虑和强迫症(OCD)症状、辅助治疗抽动秽语综合征(一种神经发育障碍)、抑郁症、睡眠障碍,并有望治疗癌症、缓解疼痛和促进心脏健康。虽然 CBD 一般来说是安全的,但它也会产生副作用,包括干扰药物代谢、影响生育能力和肝功能。此外,它可以通过口服、舌下含服、透皮或吸入等方式给药,每种给药方式的生物利用度不同。纳米技术的应用,特别是通过胶体载体系统,为最大限度地提高 CBD 的药效和药理特性带来了巨大的潜力。据报道,有使用乙醇、二氧化碳、去离子水和非极性油(如橄榄油或椰子油)提取 CBD 的方法。绿色提取方法因产量高、提取时间短、成本低而广受欢迎。由于个体因素的影响,很难确定具有理想效果的具体剂量,大多数研究建议剂量范围在 1 至 50 毫克/千克/天之间。本综述旨在探讨开发基于 CBD 的产品的原则,重点关注用于酊剂、外用药和其他药物形式的大麻素的提取方法和纯化过程,以及为实现目标而开展的进一步研究。
{"title":"Understanding the Potential of CBD for Health Benefits: an Overview.","authors":"Ivan Santos, M Beatriz P P Oliveira, Ana Casas, Javier Fidalgo, Hugo Almeida","doi":"10.2174/0115701638305553240529103622","DOIUrl":"https://doi.org/10.2174/0115701638305553240529103622","url":null,"abstract":"<p><p>Cannabinoids are compounds with increasing scientific interest, particularly due to their interaction with the endocannabinoid system via CBR1 and CBR2 receptors. They can interfere with appetite, pain, and sleep or develop mood changes of the individual. Cannabidiol (CBD) is a well-known cannabinoid with potential benefits, including reducing epilepsy seizures, alleviating anxiety, and obsessive-compulsive disorder (OCD) symptoms, aiding in Tourette Syndrome (a neurodevelopmental disorder), depression, sleep disorders, and promising in the treatment of cancer, pain relief, and heart health. Although generally safe, CBD can have side effects, including drug metabolism interference, fertility, and liver function. In addition, it can be administered by oral, sublingual, transdermal or inhalation via, each one with different bioavailability. The application of nanotechnology, specifically through colloidal carrier systems, holds promising potential for maximizing CBD's efficacy and pharmacological profile. There are reported CBD extraction methods using ethanol, carbon dioxide, deionised water, and non-polar oils like olive or coconut oil. The green extraction methods have gained popularity for their higher yields, shorter extraction time, and reduced costs. A specific dose with the desired effects is challenging due to individual factors, with most studies suggesting a range between less than 1 and 50 mg/kg/d. This review aims to explore the principles of CBD-based products development, focusing on extraction methods and purification processes of this cannabinoid for tinctures, topicals, and other pharmaceutical forms, as well as further research to attain the objectives.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141285633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phytophenols as Promoieties for Prodrug Design. 植物酚作为原药设计的促进剂。
Pub Date : 2024-05-30 DOI: 10.2174/0115701638282895240523091552
Bharat V Dhokchawle, Punit Mishra, Renny J Daniel

One lucrative method for overcoming challenges in drug discovery or for enhancing undesirable properties of already-approved medications is prodrug design. The goal of this review is to present researchers with a profile of naturally occurring Phytophenols as carriers that would be used for prodrug synthesis as well as their advantages. Phytophenols offer several advantages when used as promoieties as they also possess antioxidant and analgesic properties, they are obtained naturally and their safety profile is well established. Several phytophenols like menthol, thymol, eugenol, guaiacol, sesamol, vanillin, and umbelliferone are some of the phytophenols that have several beneficial properties and are extensively employed in the field of food processing and medicine. In the current review, we have listed all types of promoieties that are used for prodrug synthesis and phytophenols are reviewed in detail, which may help researchers to select phytophenols based on their need and suitability for drug candidates.

原药设计是克服药物发现过程中的挑战或增强已批准药物的不良特性的一种有利可图的方法。本综述旨在向研究人员介绍可用于原药合成的天然植物酚类载体及其优势。当用作原药时,植物酚具有多种优势,因为它们还具有抗氧化和镇痛特性,可以天然获取,其安全性也已得到证实。薄荷醇、百里酚、丁香酚、愈创木酚、芝麻酚、香兰素和伞形酮等几种植物酚具有多种有益特性,被广泛用于食品加工和医药领域。在本综述中,我们列出了用于原药合成的所有原药类型,并对植物酚进行了详细综述,这可能有助于研究人员根据自己的需要和候选药物的适用性来选择植物酚。
{"title":"Phytophenols as Promoieties for Prodrug Design.","authors":"Bharat V Dhokchawle, Punit Mishra, Renny J Daniel","doi":"10.2174/0115701638282895240523091552","DOIUrl":"https://doi.org/10.2174/0115701638282895240523091552","url":null,"abstract":"<p><p>One lucrative method for overcoming challenges in drug discovery or for enhancing undesirable properties of already-approved medications is prodrug design. The goal of this review is to present researchers with a profile of naturally occurring Phytophenols as carriers that would be used for prodrug synthesis as well as their advantages. Phytophenols offer several advantages when used as promoieties as they also possess antioxidant and analgesic properties, they are obtained naturally and their safety profile is well established. Several phytophenols like menthol, thymol, eugenol, guaiacol, sesamol, vanillin, and umbelliferone are some of the phytophenols that have several beneficial properties and are extensively employed in the field of food processing and medicine. In the current review, we have listed all types of promoieties that are used for prodrug synthesis and phytophenols are reviewed in detail, which may help researchers to select phytophenols based on their need and suitability for drug candidates.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141181253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vaccine Designing Technology against Leishmaniasis: Current Challenges and Implication. 利什曼病疫苗设计技术:当前的挑战和影响。
Pub Date : 2024-05-24 DOI: 10.2174/0115701638291767240513113400
Jyoti Gupta, Yukta Menon, Subodh Kumar, Chakresh Kumar Jain

Leishmaniasis, a debilitating disease caused by protozoan parasites of the genus Leishmania and transmitted by the bite of a female sandfly, continues to present significant challenges despite ongoing research and collaboration in vaccine development. The intricate interaction between the parasite's life cycle stages and the host's immunological response, namely the promastigote and amastigote forms, adds complexity to vaccine design. The quest for a potent vaccine against Leishmaniasis demands a comprehensive understanding of the immune mechanisms that confer long-lasting protection, which necessitates extensive research efforts. In this pursuit, innovative approaches such as reverse vaccinology and computer-aided design offer promising avenues for unraveling the intricacies of host-pathogen interactions and identifying effective vaccine candidates. However, numerous obstacles, including limited treatment options, the need for sustained antigenic presence, and the prevalence of co-infections, particularly with HIV, impede progress. Nevertheless, through persistent research endeavours and collaborative initiatives, the goal of developing a highly efficacious vaccine against Leishmaniasis can be achieved, offering hope through the latest Omics data development with immunoinformatics approaches for effective vaccine design for the prevention of this disease.

利什曼病是由利什曼属原生动物寄生虫引起的一种致残性疾病,通过雌性沙蝇叮咬传播,尽管疫苗开发方面的研究与合作仍在继续,但仍面临着巨大挑战。寄生虫的生命周期阶段与宿主的免疫反应(即原生体和非原生体形式)之间错综复杂的相互作用增加了疫苗设计的复杂性。要想研制出有效的利什曼病疫苗,就必须全面了解可提供持久保护的免疫机制,这就需要开展广泛的研究工作。在这一过程中,反向疫苗学和计算机辅助设计等创新方法为揭示宿主与病原体之间错综复杂的相互作用和确定有效的候选疫苗提供了一条充满希望的途径。然而,包括治疗方案有限、需要持续的抗原存在以及普遍的合并感染(尤其是与艾滋病毒的合并感染)在内的诸多障碍阻碍了研究的进展。不过,通过坚持不懈的研究努力和合作计划,开发高效利什曼病疫苗的目标是可以实现的,通过最新的 Omics 数据开发和免疫信息学方法,为有效设计预防该疾病的疫苗带来了希望。
{"title":"Vaccine Designing Technology against Leishmaniasis: Current Challenges and Implication.","authors":"Jyoti Gupta, Yukta Menon, Subodh Kumar, Chakresh Kumar Jain","doi":"10.2174/0115701638291767240513113400","DOIUrl":"10.2174/0115701638291767240513113400","url":null,"abstract":"<p><p>Leishmaniasis, a debilitating disease caused by protozoan parasites of the genus Leishmania and transmitted by the bite of a female sandfly, continues to present significant challenges despite ongoing research and collaboration in vaccine development. The intricate interaction between the parasite's life cycle stages and the host's immunological response, namely the promastigote and amastigote forms, adds complexity to vaccine design. The quest for a potent vaccine against Leishmaniasis demands a comprehensive understanding of the immune mechanisms that confer long-lasting protection, which necessitates extensive research efforts. In this pursuit, innovative approaches such as reverse vaccinology and computer-aided design offer promising avenues for unraveling the intricacies of host-pathogen interactions and identifying effective vaccine candidates. However, numerous obstacles, including limited treatment options, the need for sustained antigenic presence, and the prevalence of co-infections, particularly with HIV, impede progress. Nevertheless, through persistent research endeavours and collaborative initiatives, the goal of developing a highly efficacious vaccine against Leishmaniasis can be achieved, offering hope through the latest Omics data development with immunoinformatics approaches for effective vaccine design for the prevention of this disease.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141156040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rational Drug Discovery for Isoxazole Based VEGFR2 Inhibition. 基于异噁唑的血管内皮生长因子受体 2 抑制剂的理性药物发现。
Pub Date : 2024-05-24 DOI: 10.2174/0115701638296906240522072628
Shital M Patil, Indrani Mahadik, Shashikant V Bhandari, Kalyani D Asgaonkar, Vrushali D Randive, Aishwarya M Edake

Background: Inhibiting receptor-tyrosine-kinase (RTK) signalling pathways has emerged as a key focus of novel cancer therapy development. Vascular endothelial growth factor receptor (VEGFR) is a member of the RTK family and is required for vasculogenesis and angiogenesis. Because VEGFR 2 is the subtype responsible for cellular angiogenesis and vasculogenesis, blocking it will impair tumour cell blood supply, reducing their development, proliferation, and metastasis.

Aim & objective: The aim of this study is to obtain an optimised pharmacophore as a VEGFR2 inhibitor using QSAR investigations. This aids in determining the link between structure and activity in new chemical entities (NCEs).

Materials and methods: The multi-linear regression approach (MLR) method was utilised to generate the QSAR Model using the programme QSARINS v.2.2.4.

Results and discussion: For 2D QSAR, the best models produced has correlation coefficients of R2= 0.9396. The 3D-QSAR model obtained with R2= 0.9121 and Q2 = 0.8377. Taking docking observations, pharmacological behaviour, and toxicity analyses into account, most of the derivatives demonstrated VEGFR2 inhibitory competence.

Conclusion: According to QSAR studies, more electron-donating groups on the benzene ring linked to the isoxazole were shown to be necessary for activity. In molecular docking studies, most compounds have shown stronger affinity for the crucial amino acids Cys:919, Asp:1046, and Glu:885, which are found in typical drugs. All NCEs passed the Lipinski screening.

背景:抑制受体-酪氨酸激酶(RTK)信号通路已成为新型癌症疗法开发的重点。血管内皮生长因子受体(VEGFR)是 RTK 家族的成员,是血管生成和血管生成所必需的。由于血管内皮生长因子受体 2 是负责细胞血管生成和血管生成的亚型,因此阻断它将损害肿瘤细胞的血液供应,减少其发育、增殖和转移:本研究的目的是利用 QSAR 研究获得 VEGFR2 抑制剂的优化药代动力学。这有助于确定新化学实体(NCE)结构与活性之间的联系:材料和方法:使用 QSARINS v.2.2.4 程序,利用多线性回归方法(MLR)生成 QSAR 模型:对于二维 QSAR,所生成的最佳模型的相关系数为 R2= 0.9396。三维 QSAR 模型的 R2= 0.9121 和 Q2= 0.8377。考虑到对接观察、药理行为和毒性分析,大多数衍生物都具有抑制 VEGFR2 的能力:结论:根据 QSAR 研究,与异噁唑相连的苯环上更多的电子供能基团是活性的必要条件。在分子对接研究中,大多数化合物与典型药物中的关键氨基酸 Cys:919、Asp:1046 和 Glu:885 具有更强的亲和力。所有 NCE 都通过了利平斯基筛选。
{"title":"Rational Drug Discovery for Isoxazole Based VEGFR2 Inhibition.","authors":"Shital M Patil, Indrani Mahadik, Shashikant V Bhandari, Kalyani D Asgaonkar, Vrushali D Randive, Aishwarya M Edake","doi":"10.2174/0115701638296906240522072628","DOIUrl":"https://doi.org/10.2174/0115701638296906240522072628","url":null,"abstract":"<p><strong>Background: </strong>Inhibiting receptor-tyrosine-kinase (RTK) signalling pathways has emerged as a key focus of novel cancer therapy development. Vascular endothelial growth factor receptor (VEGFR) is a member of the RTK family and is required for vasculogenesis and angiogenesis. Because VEGFR 2 is the subtype responsible for cellular angiogenesis and vasculogenesis, blocking it will impair tumour cell blood supply, reducing their development, proliferation, and metastasis.</p><p><strong>Aim & objective: </strong>The aim of this study is to obtain an optimised pharmacophore as a VEGFR2 inhibitor using QSAR investigations. This aids in determining the link between structure and activity in new chemical entities (NCEs).</p><p><strong>Materials and methods: </strong>The multi-linear regression approach (MLR) method was utilised to generate the QSAR Model using the programme QSARINS v.2.2.4.</p><p><strong>Results and discussion: </strong>For 2D QSAR, the best models produced has correlation coefficients of R2= 0.9396. The 3D-QSAR model obtained with R2= 0.9121 and Q2 = 0.8377. Taking docking observations, pharmacological behaviour, and toxicity analyses into account, most of the derivatives demonstrated VEGFR2 inhibitory competence.</p><p><strong>Conclusion: </strong>According to QSAR studies, more electron-donating groups on the benzene ring linked to the isoxazole were shown to be necessary for activity. In molecular docking studies, most compounds have shown stronger affinity for the crucial amino acids Cys:919, Asp:1046, and Glu:885, which are found in typical drugs. All NCEs passed the Lipinski screening.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141156032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-silico Studies, Design, and Synthesis of Pyrimidine-linked Benzothiazoles for its Anticonvulsant Potential. 嘧啶连接的苯并噻唑的抗惊厥潜力的硅内研究、设计和合成。
Pub Date : 2024-05-07 DOI: 10.2174/0115701638299019240418055933
Amol Kale, Rajendra Kakde, Smita Pawar, Rutuja Thombare, Dhanashree Zope, Ishwar Kakde

Background: The objective of the study was to design and synthesize a series of N-(6-substituted-1,3-benzothiazole- 2-yl)-2-{[6-(3-substitutedphenyl)-5-cyano-2-sulfanylpyrimidine-4-yl)]amino}acetamide derivatives BPD (1-15) that contains key pharmacophores required for anticonvulsant action.

Methods: The titled compounds (BPD 1-15) were synthesized by reacting 2-substituted-N-(6-chlorobenzo[d]thiazol2-yl)acetamide with 4-amino-6-(4-substituted phenyl)-2-mercapto pyrimidine 5-carbonitrile in the presence of potassium carbonate and dry acetone. The synthesized compounds BPD (1-15) were assessed in vivo by the maximum electric shock (MES) test and the subcutaneous pentylenetetrazol (scPTZ) test in mice. The neurotoxicity test was performed by the rotarod test. A molecular docking study of title compounds with a sodium channel receptor (PDB ID: 1BYY) was carried out using the SP Docking protocol of the Glide module of the Maestro. Pharmacophore modeling was used to qualitatively identify the chemical characteristics for ligand binding and their spatial configurations in the 3D space of the active site.

Result: Among the studied compounds, BPD-15 and BPD-5 compounds showed significant action in both the MES and scPTZ models, with no neurotoxicity. BPD-15 & BPD-5 were relatively safe in acute toxicity testing. Compounds BPD-15 and BPD-5 showed good dock scores of -6.434 and -6.191, respectively.

Conclusion: Thus, the compounds BPD-15 and BPD-5 have shown a considerable affinity towards the sodium channel as compared to the standard drug Riluzole. Compound BPD-14 showed good drug compatibility, and compounds BPD-1, BPD-2, BPD-11, BPD-12, BPD-13, BPD-14, BPD-15 showed good ADME values.

背景:本研究的目的是设计和合成一系列 N-(6-取代-1,3-苯并噻唑-2-基)-2-{[6-(3-取代苯基)-5-氰基-2-硫基嘧啶-4-基)]氨基}乙酰胺衍生物 BPD (1-15),该衍生物含有抗惊厥作用所需的关键药效团:方法:在碳酸钾和干丙酮存在下,通过 2-取代-N-(6-氯苯并[d]噻唑2-基)乙酰胺与 4-氨基-6-(4-取代苯基)-2-巯基嘧啶 5-甲腈反应合成了标题化合物(BPD 1-15)。通过对小鼠进行最大电击(MES)试验和皮下注射戊四唑(scPTZ)试验,对合成的化合物 BPD(1-15)进行了体内评估。神经毒性试验是通过旋转体试验进行的。利用 Maestro 的 Glide 模块中的 SP Docking 协议,对标题化合物与钠通道受体(PDB ID:1BYY)进行了分子对接研究。药理模型用于定性鉴定配体结合的化学特征及其在活性位点三维空间中的空间构型:结果:在所研究的化合物中,BPD-15 和 BPD-5 化合物在 MES 和 scPTZ 模型中均表现出显著作用,且无神经毒性。BPD-15 和 BPD-5 在急性毒性测试中相对安全。BPD-15和BPD-5化合物显示出良好的对接得分,分别为-6.434和-6.191:因此,与标准药物利鲁唑相比,化合物 BPD-15 和 BPD-5 对钠通道具有相当大的亲和力。化合物 BPD-14 显示出良好的药物相容性,化合物 BPD-1、BPD-2、BPD-11、BPD-12、BPD-13、BPD-14 和 BPD-15 显示出良好的 ADME 值。
{"title":"In-silico Studies, Design, and Synthesis of Pyrimidine-linked Benzothiazoles for its Anticonvulsant Potential.","authors":"Amol Kale, Rajendra Kakde, Smita Pawar, Rutuja Thombare, Dhanashree Zope, Ishwar Kakde","doi":"10.2174/0115701638299019240418055933","DOIUrl":"https://doi.org/10.2174/0115701638299019240418055933","url":null,"abstract":"<p><strong>Background: </strong>The objective of the study was to design and synthesize a series of N-(6-substituted-1,3-benzothiazole- 2-yl)-2-{[6-(3-substitutedphenyl)-5-cyano-2-sulfanylpyrimidine-4-yl)]amino}acetamide derivatives BPD (1-15) that contains key pharmacophores required for anticonvulsant action.</p><p><strong>Methods: </strong>The titled compounds (BPD 1-15) were synthesized by reacting 2-substituted-N-(6-chlorobenzo[d]thiazol2-yl)acetamide with 4-amino-6-(4-substituted phenyl)-2-mercapto pyrimidine 5-carbonitrile in the presence of potassium carbonate and dry acetone. The synthesized compounds BPD (1-15) were assessed in vivo by the maximum electric shock (MES) test and the subcutaneous pentylenetetrazol (scPTZ) test in mice. The neurotoxicity test was performed by the rotarod test. A molecular docking study of title compounds with a sodium channel receptor (PDB ID: 1BYY) was carried out using the SP Docking protocol of the Glide module of the Maestro. Pharmacophore modeling was used to qualitatively identify the chemical characteristics for ligand binding and their spatial configurations in the 3D space of the active site.</p><p><strong>Result: </strong>Among the studied compounds, BPD-15 and BPD-5 compounds showed significant action in both the MES and scPTZ models, with no neurotoxicity. BPD-15 & BPD-5 were relatively safe in acute toxicity testing. Compounds BPD-15 and BPD-5 showed good dock scores of -6.434 and -6.191, respectively.</p><p><strong>Conclusion: </strong>Thus, the compounds BPD-15 and BPD-5 have shown a considerable affinity towards the sodium channel as compared to the standard drug Riluzole. Compound BPD-14 showed good drug compatibility, and compounds BPD-1, BPD-2, BPD-11, BPD-12, BPD-13, BPD-14, BPD-15 showed good ADME values.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140878164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current drug discovery technologies
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1